1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIH HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). Aims to develop safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93.
853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders 93. 395 -- Cancer Treatment Research 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research 93.
279 -- Drug Use and Addiction Research Programs 93. 273 -- Alcohol Research Programs 93. 233 -- National Center on Sleep Disorders Research 93.
840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93. 839 -- Blood Diseases and Resources Research 93. 213 -- Research and Training in Complementary and Integrative Health 93.
837 -- Cardiovascular Diseases Research 93. 838 -- Lung Diseases Research 93. 865 -- Child Health and Human Development Extramural Research 93.
867 -- Vision Research Last Updated: June 16, 2026 View version history on Grants. gov The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain.
The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope...
of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing.
This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.
Private institutions of higher education Public and state institutions of higher education Independent school districts Federally recognized Native American tribal governments Public and Indian housing authorities Special district governments City or township governments Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations For-profit organizations other than small businesses Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Grantor contact information National Institute of Neurological Disorders and Stroke (NINDS) File name Description Last updated RFA-NS-27-007-Full-Announcement. html RFA-NS-27-007-Full-Announcement.
html Jun 16, 2026 03:42 PM UTC Link to additional information Closing: February 20, 2029 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Domestic public or private, non-profit or for-profit entities, including community-based organizations, Tribes, and tribal organizations. Confirm the full requirements in the official notice before applying.
Applications for NIH HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) are due February 21, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIH HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article